Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...
Antibody-drug conjugate (RG6109) Antibody-drug conjugate (RG6148) Anti-MUC16 TDC (RG7882) Anti-TIGIT MAb (MTIG7192A, RG6058) Atezolizumab (anti-PDL1 MAb) (RG7446) BET inhibitor (TEN-010, RG6146) Bevacizumab (anti-VEGF Mab) CD20 TCB (RG6026) CD20 TDB (RG7828) CEA TCB (RG7802) Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) Codrituzumab (anti–glypican-3 MAb) (GC33, RG7686) Emactuzumab (anti–CSF-1R MAb) (RG7155) Entrectinib FAP-DR5 biMAb (RG7386) FAP-IL2v FP (RG7461) Glypican-3/CD3 biMAb (CHU) Idasanutlin (MDM2 antagonist) (RG7388) Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) Monoclonal antibody (RG6160) Monoclonal antibody (RG6194) Obinutuzumab Pan-RAF inhibitor (RG6185) Personalized cancer vaccine (RG6180) PI3K inhibitor (GDC-0077, RG6114) Polatuzumab vedotin (anti-CD79b ADC) (RG7596) Raf/MEK dual inhibitor Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) Selicrelumab (anti-CD40 MAb) (RG7876) Taselisib (PI3K inhibitor) (GDC-0032, RG7604) Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601)

US Region

International

Region

Select...
Clear All
View Results
Expand +

Tumor Type: Gastrointestinal, Gynecologic

Phase: PHASE I

Region:

Molecule:

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Anti-CEA CD3 TCB (RG7802), Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AU NCT03337698—A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
Gastrointestinal II, I Anti-CEA CD3 TCB (RG7802), Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AU
NCT03337698—A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Anti-CEA CD3 TCB (RG7802), Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) ES NCT03337698—A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
Gastrointestinal II, I Anti-CEA CD3 TCB (RG7802), Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) ES
NCT03337698—A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Anti-CEA CD3 TCB (RG7802), Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) KR NCT03337698—A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
Gastrointestinal II, I Anti-CEA CD3 TCB (RG7802), Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) KR
NCT03337698—A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Anti-CEA CD3 TCB (RG7802), Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) NY NCT03337698—A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
Gastrointestinal II, I Anti-CEA CD3 TCB (RG7802), Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) NY
NCT03337698—A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Anti-CEA CD3 TCB (RG7802), Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) TN NCT03337698—A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
Gastrointestinal II, I Anti-CEA CD3 TCB (RG7802), Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) TN
NCT03337698—A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) DE NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) DE
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FR NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FR
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) GA NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) GA
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) HU NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) HU
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) LA NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) LA
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) TN NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) TN
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) WA NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446) WA
NCT03023423—A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel AZ NCT03281369—A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel AZ
NCT03281369—A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel CA NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel CA
NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel CA NCT03281369—A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel CA
NCT03281369—A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel CT NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel CT
NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel DE NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel DE
NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel ES NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel ES
NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel KR NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel KR
NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel KR NCT03281369—A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel KR
NCT03281369—A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel MA NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel MA
NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel NY NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel NY
NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel NY NCT03281369—A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel NY
NCT03281369—A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel OR NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel OR
NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel PA NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel PA
NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel TN NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel TN
NCT03193190—A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel TN NCT03281369—A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel TN
NCT03281369—A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel TW NCT03281369—A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel TW
NCT03281369—A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel TX NCT03281369—A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)
Gastrointestinal II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Paclitaxel TX
NCT03281369—A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) AZ NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) AZ
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) CO NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) CO
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) DC NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) DC
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) GA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) GA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) IL NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) IL
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) IN NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) IN
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) MI NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) MI
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) MO NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) MO
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) NC NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) NC
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) NE NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) NE
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) OH NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) OH
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) PA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) PA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) WA NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) WA
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) WI NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446) WI
NCT02655822—Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CO NCT02876224—Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CO
NCT02876224—Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) ES NCT02876224—Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) ES
NCT02876224—Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) NY NCT02876224—Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) NY
NCT02876224—Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) TN NCT02876224—Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) TN
NCT02876224—Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) TX NCT02876224—Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) TX
NCT02876224—Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) AZ NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) AZ
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) GB NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) GB
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NY NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NY
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) OR NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) OR
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Gastrointestinal I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Gynecologic I Atezolizumab (anti-PDL1 MAb) (RG7446), BET inhibitor (TEN-010, RG6146) CA NCT03292172—A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Gynecologic I Atezolizumab (anti-PDL1 MAb) (RG7446), BET inhibitor (TEN-010, RG6146) CA
NCT03292172—A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Gynecologic I Atezolizumab (anti-PDL1 MAb) (RG7446), BET inhibitor (TEN-010, RG6146) DK NCT03292172—A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Gynecologic I Atezolizumab (anti-PDL1 MAb) (RG7446), BET inhibitor (TEN-010, RG6146) DK
NCT03292172—A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Gynecologic I Atezolizumab (anti-PDL1 MAb) (RG7446), BET inhibitor (TEN-010, RG6146) TN NCT03292172—A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Gynecologic I Atezolizumab (anti-PDL1 MAb) (RG7446), BET inhibitor (TEN-010, RG6146) TN
NCT03292172—A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
1 of 71 clinical trials
1-4 of 71 clinical trials
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
The list of international studies is not comprehensive; only international studies that also include actively enrolling US sites are listed.

Click "OK" if you wish to proceed.
CancelOK